Vecuronium

Overview

Vecuronium (Norcuron®) is a non-depolarizing neuromuscular blocking agent used in dogs and cats during general anesthesia to produce skeletal muscle relaxation. It provides paralysis of voluntary muscles without causing sedation, analgesia, or unconsciousness, and therefore must only be administered to adequately anesthetized patients.

Vecuronium is primarily used to facilitate surgical procedures requiring profound muscle relaxation, improve conditions for positive pressure ventilation, and support specialized procedures such as intraocular surgery. It has an intermediate duration of action, with neuromuscular blockade typically lasting about 20–30 minutes after a standard dose. The drug has minimal cardiovascular effects and does not trigger histamine release, making it a useful option in patients where hemodynamic stability is desired.

Recovery from neuromuscular blockade should be monitored carefully, ideally using a peripheral nerve stimulator, and reversal may be required before the end of anesthesia to ensure complete return of muscle function. Factors such as hypothermia, acidosis, and hypokalemia can prolong the duration of action, while repeated doses in healthy animals tend to show minimal cumulative effects.

Mechanism of Action (MOA): Vecuronium competitively binds to nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from activating the postjunctional membrane. This inhibits neuromuscular transmission and produces reversible skeletal muscle paralysis until the drug is metabolized or reversed.

Indications

Vecuronium is used in dogs and cats during general anesthesia when temporary skeletal muscle paralysis is required to improve surgical or anesthetic conditions.

• Neuromuscular blockade during anesthesia: Provides controlled muscle relaxation during surgical procedures.
• Facilitation of positive pressure ventilation: Improves ventilatory control in anesthetized patients requiring mechanical ventilation.
• Improved surgical access: Enhances operating conditions by eliminating voluntary muscle movement and tension.
• Intraocular surgery: Helps provide a stable surgical field during ophthalmic procedures.

Dosage (Reference)

Dog

In dogs, vecuronium is administered intravenously to produce controlled neuromuscular blockade during anesthesia. The duration and maintenance requirements depend on the initial dose and anesthetic protocol being used.

Cat

In cats, vecuronium dosing recommendations are similar to those used in dogs. Administration should be performed only in adequately anesthetized patients with ventilatory support available.

Warnings & Precautions

Vecuronium produces complete skeletal muscle paralysis without affecting consciousness, sedation, or pain perception. Appropriate anesthesia, ventilatory support, and neuromuscular monitoring are essential whenever the drug is used.

• Adequate anesthesia required: Vecuronium has no sedative, analgesic, or anesthetic properties and must never be administered to a conscious or lightly anesthetized patient.
• Mechanical ventilation: Positive pressure ventilation must be available and used as needed because respiratory muscle paralysis will occur during neuromuscular blockade.
• Neuromuscular monitoring: Monitoring with a peripheral nerve stimulator is recommended to guide dosing and confirm complete recovery before extubation and anesthetic recovery.
• Reversal before recovery: Reversal of neuromuscular blockade may be required to ensure adequate return of muscle function at the end of anesthesia.
• Hepatic disease: Vecuronium is metabolized by the liver; prolonged effects may occur in patients with hepatic dysfunction. in animals with liver dysfunction, atracurium is advised rather than vecuronium.
• Hypothermia: Reduced body temperature can significantly prolong the duration of neuromuscular blockade.
• Acid–base and electrolyte abnormalities: Acidosis and hypokalemia may enhance or prolong neuromuscular blockade and should be corrected whenever possible.
• Repeated dosing: Although cumulative effects are generally minimal in healthy animals, patients should still be monitored closely when repeated boluses or continuous infusions are used.
• Diabetic dogs: The duration of action may be shorter than expected, which can be clinically relevant during procedures requiring sustained neuromuscular blockade.
• Myasthenia gravis: In patients with MG, NMBAs should be administered with caution using doses much lower than typical (15%-20% of recommended dose) and with continuous monitoring of neuromuscular transmission.
• HIGH-ALERT drug: NMBAs should be sequestered from other medications with access limited to those familiar with their use. prominent warning labels on storage containers: ‘paralyzing agent — causes respiratory arrest’ / ‘causes respiratory paralysis; patient must be ventilated’. Inadvertent administration may cause significant harm, including death.
• Renal impairment: Use with caution in animals with severe renal dysfunction.
• Hypersensitivity: Vecuronium is contraindicated in patients hypersensitive to it.
• Pregnancy & lactation: It is unknown whether vecuronium causes fetal harm or if the drug is excreted into maternal milk. Use only when maternal benefits outweigh potential risks to offspring.

Drug Interactions

Most clinically important interactions with vecuronium involve drugs that enhance, prolong, or alter the degree of neuromuscular blockade. Close monitoring is recommended whenever these combinations are used.

• Inhalant and injectable anesthetics: Agents such as isoflurane may enhance neuromuscular blockade and reduce vecuronium requirements.
• Aminoglycoside antibiotics: Drugs such as gentamicin may prolong or potentiate neuromuscular blockade.
• Lincosamide antibiotics: Clindamycin may enhance the neuromuscular blocking effects of vecuronium.
• Tetracyclines: Agents such as doxycycline may increase the intensity or duration of neuromuscular blockade.
• Magnesium salts: Concurrent administration may significantly enhance neuromuscular blockade.
• Calcium channel blockers: Drugs such as amlodipine or diltiazem may potentiate neuromuscular blocking effects.
• Antiarrhythmic drugs: Agents including procainamide and quinidine may prolong or enhance blockade.
• Cyclosporine: May increase the duration or intensity of neuromuscular blockade.
• Medetomidine: SHORTENS the duration of vecuronium effect.
• Succinylcholine: May speed the onset of action and enhance the neuromuscular blocking actions of vecuronium. Do NOT give vecuronium until succinylcholine effects have subsided.
• Other non-depolarizing relaxants: May have a synergistic effect when combined with vecuronium.
• Bacitracin / Polymyxin B (systemic): May enhance or prolong vecuronium’s neuromuscular blocking activity. Consider therapy modification.
• Vancomycin: May enhance or prolong vecuronium’s neuromuscular blocking activity.
• Lincomycin: enhancing neuromuscular blockade.

Side Effects & Overdose

Side Effects

Vecuronium is generally well tolerated in dogs and cats. Most adverse effects are related to its intended neuromuscular blocking action rather than direct cardiovascular or respiratory toxicity.

• Respiratory paralysis: Expected during neuromuscular blockade and requires assisted or controlled ventilation until adequate spontaneous respiration returns.
• Prolonged neuromuscular blockade: Recovery may be delayed, particularly in patients with hypothermia, acidosis, hypokalemia, or hepatic dysfunction.
• Residual muscle weakness: Incomplete recovery can result in weakness, reduced ventilatory function, or delayed anesthetic recovery if neuromuscular function is not adequately monitored.

Overdose

Excessive doses primarily result in prolonged and profound neuromuscular blockade. Cardiovascular adverse effects are uncommon because vecuronium has minimal effects on heart rate, blood pressure, and histamine release.

• Prolonged paralysis: Markedly extended skeletal muscle and respiratory muscle paralysis may occur.
• Apnea: Complete loss of spontaneous ventilation requiring mechanical respiratory support.
• Delayed recovery: Neuromuscular function may remain impaired for an extended period following excessive dosing or continuous infusion.
• Management: Maintain anesthesia, provide positive pressure ventilation, and monitor neuromuscular function until recovery is confirmed. monitor blood pressure, heart rate, ventilation, oxygenation (end-tidal CO&sub2;, SpO&sub2;, blood gas) with supportive treatment as needed.
• Reversal agents: Anticholinesterase (e.g. neostigmine) + anticholinergic (e.g. atropine / glycopyrrolate) is the conventional reversal. Edrophonium reversal failure has been reported in a published case report.
• LD50 data: IV LD50 of 0.051 mg/kg in mice and 0.2 mg/kg in rats.
• 24-hour poison consult: For severe overdose, consult a 24-hour veterinary poison control center due to the potential complexity of NMBA toxicity management.

Key Notes

Practical clinical points that help optimize the use of vecuronium in dogs and cats during anesthesia:

• No effect on anesthetic depth: Muscle paralysis can make a patient appear adequately anesthetized when anesthetic depth is actually inadequate; always assess anesthesia using appropriate physiologic parameters.
• Excellent operating conditions: Provides profound muscle relaxation without causing cardiovascular instability, making it useful for procedures requiring a motionless surgical field.
• Predictable duration: The intermediate duration of action allows good control of neuromuscular blockade with either intermittent boluses or continuous infusion techniques.
• Minimal histamine release: Unlike some neuromuscular blocking agents, vecuronium is unlikely to cause clinically significant histamine-mediated effects.
• Suitable for infusion protocols: Continuous rate infusions can provide stable neuromuscular blockade during lengthy procedures with relatively little drug accumulation in healthy patients.
• Sugammadex compatibility: Neuromuscular blockade can be reversed with sugammadex 8 mg/kg IV when rapid recovery is desired or clinically necessary.
• Ophthalmic surgery: Particularly useful when complete ocular immobility and optimal surgical conditions are required.
• PK summary: Hepatic metabolism. Intermediate duration ~20-30 min after 0.1 mg/kg. Shorter duration in diabetic dogs . Prolonged in hepatic or biliary disease ( reduce dose).
• Storage + reconstitution: Store powder at 20-25°C protected from light. After reconstitution with sterile water for injection, vecuronium is stable for 24 h at 2-8°C refrigerated. Contains no preservative — discard unused portions after reconstitution.
• Compatibility — alkaline-precipitation warning: compatible with 0.9% NaCl, 5% dextrose in water, 5% dextrose in 0.9% NaCl, and Lactated Ringer’s for dilution. NEVER mix in the same IV bag, syringe, or through the same needle with alkaline drugs (e.g. barbiturates) or alkaline solutions (e.g. sodium bicarbonate) — precipitation may occur.
• Atracurium preferred in hepatic dysfunction: atr.acurium undergoes Hofmann elimination (organ-independent), whereas vecuronium relies on hepatic metabolism